Online ISSN: 1949-2553
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

Oncotarget | HALP Score: Prognostic Ability in Cancers – A Literature Review

News

March 6, 2023
PRESS RELEASE: On February 25, 2023, Oncotarget published a new review, entitled, “What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types.” continue reading »

Oncotarget | Unveiling the Non-canonical Functions of EZH2 in Prostate Cancer

News

March 3, 2023
PRESS RELEASE: On February 11, 2023, researchers from Northwestern University published a new editorial in Oncotarget, entitled, “Unveiling the non-canonical functions of EZH2 in prostate cancer.” continue reading »

Oncotarget | WNT-pathway Medulloblastoma: What Constitutes Low-risk and How Low Can One Go?

News

February 27, 2023
PRESS RELEASE: On February 7, 2023, a new research perspective was published in Oncotarget, entitled, “WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?” continue reading »

Oncotarget | Oncogenic Driver FGFR3-TACC3 Requires 5 Coiled-coil Heptads for Activation and Disulfide Bonds for Stability

News

February 23, 2023
PRESS RELEASE: On February 11, 2023, a new research paper was published in Oncotarget, entitled, “Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.” continue reading »